on Nanohale AG (ETR:FYB)
Formycon Expands Biosimilar Portfolio with Tezspire® and Hemlibra®
Formycon AG has announced its latest biosimilar candidates, FYB210 and FYB286, targeting the well-regarded drugs Tezspire® and Hemlibra®. FYB210, a biosimilar to Tezspire®, addresses treatments for severe asthma and potential applications in COPD, a leading cause of global mortality. FYB286, a biosimilar to Hemlibra®, is designed to manage bleeding in hemophilia A, yet no biosimilars for bispecific antibodies have received US or EU approval.
Tezspire® sales soared to USD 1.9 billion in 2025. Meanwhile, Hemlibra® achieved USD 5.7 billion, highlighting significant market demand. Globally, an estimated 75% of hemophilia cases remain undiagnosed. These additions reinforce Formycon's Smart Portfolio strategy, blending blockbusters with niche therapies, reflecting their ambition to broaden access to critical medical treatments.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Nanohale AG news